A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma by Tedeschi, R et al.
Kaposi’s sarcoma associated herpesvirus (KSHV), also denoted
HHV8, is a γ -herpesvirus closely associated with Kaposi’s
sarcoma (KS), body-cavity-based lymphoma and multicentric
Castleman’s disease (Cesarman et al, 1995; Moore and Chang,
1995). An association has been reported also between multiple
myeloma (MM) and HHV8 (Rettig et al, 1997), based on presence
of HHV8 DNA in dendritic cells in the bone marrow of MM
patients, but not of healthy subjects. This finding was confirmed in
some reports (Said et al, 1997; Chauhan et al, 1999) but not in
others (MacKenzie et al, 1997; Parravicini et al, 1997; Mitterer
et al, 1998). HHV8 encodes a homologue of the cytokine IL-6,
known to be required for MM pathogenesis (Moore et al, 1996;
Burger et al, 1998), and expression of the viral IL-6 has been
reported in dendritic cells of MM patients, providing a plausible
hypothesis on a mechanism whereby HHV8 might be involved in
MM pathogenesis. 
Several serologic studies using both immunofluorescence
assays (IFA) and ELISA methods have reported a lack of associa-
tion between HHV8 and MM (Masood et al, 1997; MacKenzie et
al, 1997; Parravicini et al, 1997; Bouscary et al, 1998; Perna et al,
1998; Santarelli et al, 1998). Only one study (Gao et al, 1998),
using a Western blot assay with recombinant ORF65 and ORF73
antigens, reported an increased seroprevalence for HHV8 in MM
patients, with 81% and 52% of reactivity against ORF65 and
ORF73 respectively, as compared to 6% and 2% among healthy
control subjects. However, none of these studies were prospective
in design. Prospective studies can provide information on tempor-
ality and can avoid several sources of selection bias. Furthermore,
the possibility exists that the hypergammaglobulinemia seen in
MM may have affected serological measurements, causing differ-
ential misclassification bias. 
To evaluate whether HHV8 infection is associated with an
increased risk of MM, avoiding the possibility that the presence
of the MM disease might affect measurements, we performed a
prospective study nested in a cohort of 39 057 healthy individuals
that were followed up for 23 years. For comprehensive evaluation,
HHV8 infection was scored both using modern Western blot
assays based on recombinant major immunogenic HHV8 proteins
(ORF65, ORF K8.1A and ORF73) as well as the reference
method, monoclonal antibody-enhanced immunofluorescence
assay (mIFA) for lytic and latent HHV8 antigens. 
MATERIALS AND METHODS 
Study design 
Between 1968 and 1972 the Mobile Clinic of the Social Insurance
Institution of Finland performed a health survey on a population-
based sample of 20 243 men and 18 814 women resident in most
parts of Finland. The survey included a health interview (including
marital status and smoking status), some routine physiological
measurements (such as body-mass index) and collection of serum
sample (Knekt et al, 1988). A registry linkage of the serum bank
with the files of the nationwide Finnish Cancer Registry identified
47 myeloma cases during a follow-up to the end of 1991. For each
MM patient, 5 control subjects who were free of any cancer at
baseline and who remained alive and free of myeloma up to the
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matched for gender, age and municipality of residence. Due to the
way the cohort was enrolled, the matching for municipality of
residence also matched for the time of sample collection. Controls
closest in age to the corresponding case were selected. In 79% of
the case-control sets the maximal difference between the cases and
controls was one year; in 9% of sets it was 3 years or more.
Altogether, the serum samples of 224 controls were found and
included in the study. The patients gave informed consent at enrol-
ment, the registry linkages were approved by the Computer
Inspection Agency and the study by the Institutional Review
Board. 
The serum samples were coded and analysed without know-
ledge of the identity of the samples. The serological results were
sent to the National Public Health Institute in Helsinki, Finland,
where the code was broken and the results were statistically
analysed. 
Proteins 
4 antigens were used in the Western blot assays: GST (glutathione-
S-transferase), ORF65, ORF73 and ORFK8.1A. GST was used as
a negative control, as any antibody response to this protein in the
tested sera is not KSHV specific. 
ORF73 
A 418 nucleotide long fragment (from the C-terminus) from
ORF73 was PCR-amplified using a 5′ primer (GAGGATCC-
GAATACCGCTATGTACTCAG) and a 3′ primer (CTGAATTCC-
TAGGCGGGCCATTTGTACT) in glass capillaries using a Rapid
Cycler (Idaho Technologies). Amplified fragments were subcloned
into the LNA-GST2TK (or PGEX 2TK) vector (Pharmacia). The
bacterial cultures were grown in fresh LB medium (0.2% glucose
and 100 µ g ml-1 AMP) for two hours at 37˚C. Induction of fusion
protein was done by adding isopropyl-beta-D-thiogalacto-
pyranoside (IPTG) 0.3 mM for 45 minutes at 37˚C. The protein
was purified using Glutatione Sepharose. 
ORF65 
A recombinant ORF65 protein (aa 86–170) was fused to the
carboxy-terminal end of mouse dihydrofolate reductase, placed
under control of the T7 promoter in the expression vector pQE 42
(Qiagen, Hilden, Germany), which provides a histidine tag at the
aminoterminal end of the fusion protein. The protein was purified
to homogeneity using affinity chromatography on Ni-NTA resin
(Qiagen) (Simpson et al, 1996). 
ORFK8.1A 
Purified K8.1A protein was generously provided by Dr Bala
Chandran, Dept. of Microbiology, Molecular Genetics and Im-
munology, the University of Kansas Medical Center, Kansas City,
Kansas. ORFs K8.1A and K8.1B had been amplified using a 5’
primer (CGGGGATCCATGAGTTCCACACAGATTCGC) and a
3’ primer (ATGGTCTCGAGTTACACTATGTAGGGTTTC). Am-
plified PCR fragments had been purified and ligated into pGEM-T
vector (Promega) and orientation verified by restriction enzyme
digestion and sequence analysis. These plasmids had been
digested with BamH1 and Xhol and inserted into the GST expres-
sion vector pGEX-4T-1 and orientation verified by restriction
enzyme digestion. Induction of fusion protein was done by adding
IPTG (1 mM) to bacterial cultures grown to an OD600 of 0.2–0.5.
The induced GST-ORFK8.1A fusion protein had been puri-
fied using Glutatione Sepharose 4B (Pharmacia) (Chandran et al,
1998). 
Western blot assay 
271 coded serum samples were tested in the WB reactions in a
blinded manner against the antigens GST, ORF65, ORF73 and
ORFK8.1A. In each batch of analysis, 10 serum samples and 2
positive controls (pools of serum samples) were used: pool 1
consisted of sera from 6 KS-positive and HIV-negative patients;
pool 2 consisted of sera from 5 KS-positive and HIV-positive
patients. 
The protein samples were separated using SDS-PAGE, 10–15%
polyacrylamide gradient gels and electrophoretically transferred to
nitrocellulose sheets. After the transfer, the nitrocellulose sheets
were cut into 12 strips and blocked with 5% non-fat dry milk in
PBS (MilkPBS), for 1 h at room temperature (RT). Human sera
(1:50 diluted in 2% MilkPBS) were then incubated with the strips
for 2 h at RT, shaking. The strips were washed 5 times with 5%
non-fat dry milk and finally incubated for 30 minutes with goat
anti-human IgG HRP conjugate (Dako), diluted 1/1000 in 2%
MilkPBS. After three washes with 2% MilkPBS and several
washes with PBS-0.5% Tween20, bound enzyme-labelled anti-
bodies were detected using ECL Western blotting detection
reagent (Amersham), according to the manufacturer’s instructions. 
Immunofluorescence assay 
IFA was performed as described (Lennette et al, 1996). Briefly, 107
HHV8-carrying BCBL-1 cells or HHV8-negative Ramos cells in 10
ml of medium were induced with 10 ng ml–1 TPA (Sigma) and 200
UI ml–1 IL-6 (Beckton Dickinson) for 5 days. TPA-induced BCBL-1
and Ramos cells were collected and washed in PBS and smeared on
coverslips, air dried and fixed in acetone. Slides were incubated
successively in 3 steps of 30 minutes each at 37˚C with the test
serum diluted 1:10, with mouse monoclonal anti-human IgG 1, 2, 3
(ATCC HP6058) and then with FITC-labelled anti-mouse antibodies
(1:80 diluted; Sigma) and Evans’ blue counterstain. Two indepen-
dent observers scored lytic and latent seropositivities. Specific gran-
ular punctate nuclear fluorescence with the majority (>80%) and
bright cytoplasmic fluorescence with about 30% of the BCBL-1
cells were considered as recognizing latent and lytic HHV8 anti-
gens, respectively (Lennette et al, 1996). Sera were tested with a
starting dilution of 1:10 and then titred with 4-fold serum dilutions.
Sera that showed non-specific fluorescence against the Ramos cell
negative control were scored as not specifically reactive. 
Statistical analysis 
The laboratory results were transmitted to the Finnish Social
Insurance Institution where the code was broken and the relative
risk (RR) of developing MM given HHV8 seropositivity was
estimated using conditional logistic regression. 
RESULTS 
Validation of the sensitivities of the serologic tests 
The sensitivities of the assays were evaluated using sera from 45
AIDS patients and 10 HIV-negative patients attending the Division
of AIDS & Medical Oncology at the Centro di Riferimento
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Oncologico in Aviano with the diagnosis of KS and 17 serum
samples from HIV-negative patients with KS collected in
1973–1974 in Kenya (Table 1). The sensitivities ranged from 33%
for ORF73 Western blot to 93% for lytic immunofluorescence,
which is comparable to what has been reported in previous studies. 
Comparison of reactivities of sera with HHV8 infected
BCBL-1 cells on mIFA and with the recombinant HHV8
proteins on Western Blot Assay 
Altogether 20/271 (7.4%) serum samples from the prospective
study were reactive with at least one HHV8 recombinant protein in
WB. 
In immunofluorescence, 18% (46 of 271) of the serum samples
were positive only for the lytic IFA antibodies and 1% (3 of 271)
were positive for both the latent and lytic IFA antibodies. The titres
ranged from 1:10 to ≥ 1:640. 
The level of agreement among mIFA (lytic or latent) and WB
(considering the reactivity against at least one antigen) was not
very high (Odds Ratio = 12.36, CI: 5.36–28.08) (Table 2).
Immunofluorescence identified more samples as positive (49 vs
20); 13 samples were concordantly positive and 209 concordantly
negative, on both of these tests. 
Risk of multiple myeloma among HHV8 seropositive
subjects 
Western blot seropositivity had no association with subsequent
MM occurrence (RR: 0.89, CI: 0.25–3.25). The point estimates of
the RR for the different antigens varied from 0.37 for ORF65 to
3.18 for ORFK8.1A, but none of the RRs were significantly
different from unity. Only 7 samples were concomitantly positive
for >1 antigen in Western blot. Positivity for multiple antigens was
not associated with MM (RR: 0.96; CI: 0.10–8.82). The estimated
relative risk for MM was increased both for the lytic and for the
latent immunofluorescence (OR: 2.0 and 10.0, respectively), albeit
this was not statistically significant (Table 3). 
The immunofluorescence positive serum samples and a random
subset of 16 negative serum samples were subjected to repeat
analysis. The negative samples again tested negative. The positive
samples tested positive again, although only in 32 cases was the titre
the same. 11 serum samples had a lower titre by one dilution step and
four serum samples a higher titre by one dilution step. The Western
blot positive sera were also retested with confirmatory results. 
DISCUSSION 
We aimed to evaluate whether HHV8 infection was associated
with an increased risk for multiple myeloma. Since the initial
report that hypothesized that KSHV causes MM through infection
of bone marrow stromal dendritic cells and possible paracrine
effects of viral IL-6 (Rettig et al, 1997), several studies have
addressed the presence of HHV8 DNA in bone marrow cells and
Table 1 Reactivity of human Kaposi’s sarcoma sera with HHV8 ORFs K8.1A, 65 and 73 recombinant proteins on Western blot
and IFA assays 
N˚ WB ORFs WB WB WB IFA IFA 
K8.1A/65/73 ORFK8.1A ORF65 ORF73 Latent Lytic 
positive positive positive positive positive positive 
KS 45 37 (82%) 26 (58%) 29 (64%) 12 (27%) 21 (47%) 42 (93%) 
HIV+
Italy 
KS 10 10 (100%) 7 (70%) 10 (100%) 5 (50%)  7 (70%) 9 (90%) 
HIV 
Italy 
KS 17 16 (94%) 15 (88%) 9 (53%) 7 (41%)  16 (94%) 16 (94%) 
HIV 
Africa 
Total 72 63 (88%) 48 (67%) 48 (67%) 24 (33%) 44 (61%) 67 (93%) 
Table 2 Comparison between IFA and Western blot HHV8 reactivity 
WB WB ORF65 WB ORF73 IFA IFA 
ORFK8.1A LYT LAT 
WB ORFK8.1A 1.0 –– – –  
WB ORF65 0.34* 1.0 –– –  
WB ORF73 0.15* 0.11* 1.0 ––  
IFA LYT 0.29* 0.34* 0.10 1.0 – 
IFA LAT 0.18* 0.14* 0.28* 0.22* 1.0 
Spearman correlation coefficients; *: P < 0.05. 
Table 3 HHV8 seropositivity and risk of multiple myeloma 
Multiple  Healthy on RR 95% CI
myeloma on  follow-up
follow-up
IFA lytic No 34 188 Ref. 
Yes 13 36 2.02 0.94–4.33 
IFA latent No 45 223 Ref. 
Yes 2 1 10.00 0.91–110.29 
WB: any one  No 44 208  Ref. 
of ORF65,  Yes 3 16 0.89 0.25–3.25 
ORF73 or 
ORFK8.1A
WB ORF65 No 46 212 Ref. 
Yes 1 12 0.37 0.05–2.99 
WB ORF73 No 47 220 Ref. 
Yes 0 4 0.00 0.00 
WB ORF No 44 219 Ref. 
K 8.1A Yes 3 5 3.18 0.70–14.47HHV8 and risk of multiple myeloma 125
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HHV8 seroprevalences among MM patients, with mixed results.
The most likely reasons for mixed results are different reliabilities
of the serological methods used and selection biases in studies
performed without a formal study base definition. 
Our serologic study evaluated whether HHV8 infection is asso-
ciated with increased risk for multiple myeloma in a defined
cohort of 39 057 subjects that were followed up for 23 years. The
prospective study design avoided the possibility that MM disease
itself might affect serological measurements. For example, the
markedly decreased general humoral response in this disease
might impair HHV8 antibody response. A 20-year follow-up may
be required to evaluate the impact of infection on emergence of
virus-associated cancers (zur Hausen, 1999). 
Our serological evaluation used several of the different HHV8
antibody detection methods: Western blot assay based on 3
different recombinant proteins as well as immunofluorescence.
The different rates of HHV8 seroprevalence using different
methods is likely to reflect differences in assay sensitivities, speci-
ficities and/or reproducibilities (Rabkin et al, 1997). Repeat testing
of the same samples at a later time point did not find any note-
worthy differences in the reproducibility of the different tests used.
The positive control serum panel of patients with KS was used for
within-study validation of sensitivity. As it is not possible to define
serum panels of definitely unexposed persons, the population-
based healthy controls of the study could be used for a crude esti-
mation of specificity. It is interesting to note that if the validity of
the assays is ranked by odds ratios for association with KS in
comparison with healthy controls, the different serological assays
rank in the order latent IF, ORF K8.1 WB, lytic IF, ORF 65 WB and
ORF73 WB, suggesting that the validity of the assay correlates with
the point estimate of the multiple myeloma risk (cf.Table 3). 
In conclusion, HHV8 seropositive persons were not found to be
at increased risk of MM. Since the statistical power of our study
was limited, further studies may be warranted to evaluate whether
HHV8 infection is associated with MM. 
ACKNOWLEDGEMENTS 
Grant Support: RT is supported by the Foundation Blanceflor
Ludovisi, nee’ Bildt. TFS was supported by the NHS Biomedical
Research Fund, RDO/22/9. 
REFERENCES 
Bouscary D, Dupin N, Fichelson S, Grandadam M, Fontenay-Roupie M, Marcelin
AG, Blanche P, Picard F, Freyssinier JM, Ravaud P, Dreyfus F and Calvez V
(1998) Lack of evidence of an association between HHV-8 and Multiple
Myeloma. Leukemia 12: 1840–1841 
Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Calden JR and
Gramatzki M (1998) Human Herpesvirus type 8 interleukin-6 homologue is
functionally active on human myeloma cells. Blood 91: 1858–1863 
Cesarman E, Chang Y, Moore PS, Said JW and Knowles DM (1995) Kaposi’s
sarcoma associated herpesvirus-like DNA sequences in AIDS-related body
cavity based lymphomas. New Engl J Med 332: 1186–1191 
Chandran B, Bloomer C, Chan SR, Zhu L, Goldstein E and Horvat R (1998) Human
Herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated
by spliced transcripts. Virology 249: 140–149 
Chauhan D, Bharti A, Raje N, Gustafson E, Pinkus JL, Teoh G, Hideshima T, Treon
SP, Fingeroth JD and Anderson KC (1999) Detection of Kaposi’s sarcoma
herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.
Blood 93(5): 1482–1486 
Gao SJ, Alsina M, Deng JH, Harrison CR, Montalvo EA, Leach CT, Roodman GD
and Jenson HB (1998) Antibodies to Kaposi’s sarcoma-associated Herpesvirus
(Human Herpesvirus 8) in patients with Multiple Myeloma. J Infect Dis 178:
846–849 
Knekt P, Aromaa A, Maatela J, Aaran RK, Nikkari T, Hakama M, Hakulinen T,
Peto R, Saxen E and Teppo L (1988) Serum vitamin E and risk of cancer
among Finnish men during a 10 year follow-up. Am J Epidemiol
127(1): 28–41 
Lennette ET, Blackbourn DJ and Levy JA (1996) Antibodies to Human herpesvirus
type 8 in the general population and in Kaposi’s sarcoma patients. Lancet 348:
858–861 
MacKenzie J, Sheldon J, Morgan G, Cook G, Schulz TF and Jarrett RF (1997) HHV-
8 and multiple myeloma in the UK. Lancet 350: 1144–1145 
Masood R, Zheng A, Arora N, Chatlynne L, Handy M, Whitman J, Kaplan M, Dosik
M, Ablashi DV and Gill PS (1997) Kaposi’s sarcoma associated Herpesvirus
infection and multiple myelomas. Science 278: 1970–1971 
Mitterer M, Mair W, Gatti D, Sheldon J, Vachula M, Coser P and Schulz TF (1998)
Dendritic cells derived from the bone marrow and CD34+ selected blood
progenitor cells of myeloma patients, cultured in serum-free media, do not
contain the Kaposi’s sarcoma herpesvirus genome. Br J Haematol 102:
1338–1342 
Moore PS and Chang Y (1995) Detection of herpesvirus-like DNA sequences in
Kaposi’s sarcoma patients with and without HIV infection. New Engl J Med
332: 1181–1185 
Moore PS, Boshoff C, Weiss RA and Chang Y (1996) Molecular mimicry of human
cytokine and cytokine response pathway genes by KSHV. Science 274:
1739–1744 
Parravicini C, Lauri E, Baldini L, Neri A, Poli F, Sirchia G, Morono M, Galli M and
Corbellino M (1997) Kaposi’s sarcoma-associated Herpesvirus infection and
Multiple Myeloma. Science 278: 1969–1973 
Perna AM, Viviano E, Iannitto E, Marcenò R and Romano N (1998) No association
between Human Herpesvirus type 8 infection and Multiple Myeloma. J Natl
Cancer Inst 90(13): 1013–1014 
Rabkin CS, Schulz TF, Whitby D, Lennette ET, Magpantay LI, Chatlynne L and
Biggar R (1997) Interassay correlation of Human Herpesvirus 8 serologic tests.
J Infect Dis 178: 304–309 
Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo
C, Wu C, Fraser J and Said JW (1997) Kaposi’s sarcoma associated
Herpesvirus infection of bone marrow dendritic cells from multiple myeloma.
Science 276: 1851–1854 
Said JW, Rettig MR, Heppner K, Vescio RA, Schiller G, Ma HJ, Belson D, Savage
A, Shintaku IP, Koeffler HP, Asou H, Pinkus G, Pinkus J, Schrage M, Green E
and Berenson JR (1997) Localization of Kaposi’s sarcoma-associated
herpesvirus in bone marrow biopsy samples from patients with multiple
myeloma. Blood 90: 4278–4282 
Santarelli R, Angeloni A, Farina A, Gonnella R, Gentile G, Martino P, Petrucci MT,
Mandelli F, Frati L and Faggioni A (1998) Lack of serologic association
between Human Herpesvirus-8 infection and multiple myeloma and
monoclonal gammopathies of undetermined significance. J Natl Cancer Inst 90
(10): 781–782 
Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, Rainbow L, Howard MR,
Gao SJ, Bohenzky RA, Simmonds P, Lee C, de Ruiter A, Hatzakis A,
Tedder RS, Weller IVD, Weiss R and Moore P (1996) Prevalence of Kaposis’s
sarcoma associated Herpesvirus infection measured by antibodies to
recombinant capsid protein and latent immunofluorescent antigen. Lancet 349:
1133–1138 
zur Hausen H (1999) Viruses in human cancers. Eur J Cancer 35: 1174–1181